Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid.
Matthew R MeyerKristopher M KirmessStephanie EastwoodTraci L Wente-RothFaith IrvinMary S HolubaschVenky VenkateshIlana FogelmanMark MonaneLucy HannaGil D RabinoviciBarry A SiegelRachel A WhitmerCharles ApgarRandall J BatemanDavid M HoltzmanMichael IrizarryDavid VerbelPallavi SachdevSatoshi ItoJohn ContoisKevin E YarasheskiJoel B BraunsteinPhilip B VergheseTim WestPublished in: Alzheimer's & dementia : the journal of the Alzheimer's Association (2024)
The PrecivityAD2 blood test showed strong clinical validity, with excellent agreement with brain amyloidosis by PET.